Browse > Article
http://dx.doi.org/10.5352/JLS.2006.16.5.799

Susceptibilities of Quinolones against Erythromycin- and Tetracycline-Resistant Mycoplasma pneumoniae Isolates  

Chang, Myung-Woong (Department of Microbiology, Kosin University College of Medicine)
Park, In-Dal (Department of Microbiology, Kosin University College of Medicine)
Kim, Kwang-Hyuk (Department of Microbiology, Kosin University College of Medicine)
Publication Information
Journal of Life Science / v.16, no.5, 2006 , pp. 799-805 More about this Journal
Abstract
The in vitro activities of quinolones were determined with 36 strains of tetracycline- resistant, 39 strains of erythromycin-resistant, 21 strains of both resistant to tetracycline and erythromycin, and 27 strains of both susceptible to tetracycline and erythromycin of the M. pneumoniae isolates which have been isolated and classified in previous studies. The $MIC_{90}$ of moxifloxacin, levofloxacin, sparfloxacin, ofloxacin, ciprofloxacin, amikacin, and clarithromycin against 36 strains of tetracycline-resistant M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 15.6, and $1.56\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 39 strains of eryhtromycin-resistant M. pneumoniae isolates were 0.06, 0.39, 0.125, 1.0, 1.0, 15.6, and $25.0\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 21 strains of both resistant to tetracycline and eryhtromycin of M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 3.9, and $1.56\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 27 strains of both susceptible to tetracycline and eryhtromycin of M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 7.8, and $0.09\;{\mu}g/ml$, respectively. These result suggest that moxifloxacin, levofloxacin, and sparfloxacin of the quinolones might be promising antimicrobial agents for the treatment of tetracycline- and erythromycin-resistant M. pneumoniae infection. However, selection of ofloxacin, ciprofloxacin, and clarithromycin for the treatment of M. pneumoniae infection should be cautious decision with antimycoplasmal susceptibility test.
Keywords
Mycoplasma pneumoniae; antimycoplasmal susceptibilities; quinolones;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Krause D. C., and D. Taylor-Robinson. 1992. Mycoplasma which infect humans. pp417-444, In Maniloff J. (ed), Mycoplasmas, ASM, Washington
2 Roberts M. C., L. A. Koutsky, K. K. Holmes, D. J. LeBlanc, and G. E. Kenny. 1985. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob. Agents Chemother, 28, 141-143   DOI   ScienceOn
3 Okazaki, N., M. Narita, S. Yamada, K. Izumikawa, M. Umetsu, T. Kenri, Y. Sasaki, Y. Arakawa, and T. Sasaki. 2001. Characteristics of macrolide-resistant M. pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45, 617-620   DOI
4 Park I. D., K. H. Kim, M. W. Chang, and H. S. Park. 1992. Distribution of tetM gene in the tetracycline resistant Bacteria. J. Korean Soc. Microbiol. 27, 59-72
5 Arai, S. and Y. Tokitsu. 1995. Antimycoplasmacidal activity of new quinolones in vitro and in vivo. Jap. J. Mycoplasmol. 21, 37-38
6 Hamamoto K., T. Shimizu, N. Fujimoto, Y. Zhang, and S. Arai. 2001. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 4,: 1908-1910
7 Duffy L. B., D. M. Crabb, X. Bing, and K. B. Waites. 2003. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 52, 527-528   DOI   ScienceOn
8 Matsuoka, M., M. Narita, N. Okazki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, and T. Sasaki. 2004. Characterization and molecular analysis of macrolide- resistant M. pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48, 4624-4630   DOI   ScienceOn
9 Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob. Agents Chemother. 47, 39-42   DOI
10 Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39, 577-585   DOI   ScienceOn
11 Pereyre, S., C. Guyot, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2004. In vitro selection and characterization of resistance to macrolides and related antibiotics in M. pneumoniae. Antimicrob. Agents Chemother. 48, 460-465   DOI
12 Shames J. M., R. B. George, W. B. Holliday, J. R. Rasch, and W. J. Mogabgab. 1970. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch. Intern. Med. 125, 680-684   DOI
13 Suyama, N., K. Ishida, M. Kaku, K. Izumikawa, and K. Hara. 1995. Therapeutic activites of macrolides against M. pneumoniae infection. Jap. J. Mycoplasmol. 21, 39-40
14 Izumikawa K., Y. Hirakata, T. Yamaguchi, R. Yoshida, H. Tanaka, H. Takemura, S. Maesaki, K. Tomono, M. Kaku, K. I. Izumikawa, S. Kamihira, and S. Kohono. 1998. In vitro activities of quinupristin-dalfopristin and the strteptogramin RPR 106972 against M. pneumoniae. Antimicrob. Agents Chemother. 42, 698-699
15 Chang M. W., K. H. Kim, I. D. Park, G. Y. Song, S. W. Kim, M. H. Joh, and C. E. Choi. 2005. Isolation of Mycoplasma pneumoniae and antimicrobial susceptibilities of the isolates(III). J. Life Sci. 15, 479-485   과학기술학회마을   DOI   ScienceOn
16 Vester, B. and S. Douthwaite. 2001. Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrob. Agents Chemother. 45, 1-12   DOI
17 Waites, K. B., L. B. Duffy, T. Schmid, D. Carb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, M. hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35, 1181-1185   DOI   ScienceOn
18 Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents. 21, 574-577   DOI   ScienceOn
19 Waites K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobials against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47, 161-165   DOI
20 Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, and et al. 1994. In vitro activities of sparfloxacin against M. pneumoniae. Antimicrob. Agents Chemother. 38, 738-741   DOI   ScienceOn
21 Kenny, G. E. and F. D. Cartwright. 1994. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to new glycycyclines in comparison with those to older tetracyclines. Antimicrob. Agents Chemother. 38, 2628-2632   DOI   ScienceOn
22 Niitu Y., S. Hasegawa , T. Suetake, H. Kubota, S. Komatu, and M. Horikawa. 1970. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76, 434-443
23 Pereyre, S., P. Gonzalez, B. de Barbeyrac, A. Darnige, H. Renaudin, A. Charron, S. Raherison, and C. M. Bebear, 2002. Mutation in 23S rRNA account for intrindic resistance to macrolides in M. hominis and M. fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob. Agents Chemother. 46, 3142-3150   DOI
24 Kenny, G. E. and F. D. Cartwright, 1996. Susceptibilities of M. pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to new quinolone, trovafloxacin(CP-99219). Antimicrob. Agents Chemother. 40, 1048-1049
25 Lucier, T. S., K. Heitzman, S. K. Liu, and P. C. Hu. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of M. pneumoniae. Antimicrob. Agents Chemother. 39, 2770-2773   DOI   ScienceOn
26 MacGowan A. P. 1999. Moxifloxacin(Bay 12-8039): a new methoxy quinolone antibacterial. Expert. Opin. Investig. Drugs. 8, 181-199   DOI   ScienceOn
27 Morozumi M., K. Hasegawa, R. Kobayashi, N. Inoue, S. Iwata, H. Kuroki, N. Kawamura, E. Nakayama, T. Tajima, K. Shimizu, and K. Ubukata. 2005. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49, 2302-2306   DOI   ScienceOn
28 Blanchard A., and C. Bebear. 2002. Mycoplasmas of human, pp 45-71, In Razin S, and Hermann R (ed), Molecular biology and pathogenicity of mycoplasma. Kluwer Academic Pub., New York
29 Cassell, G. H., W. A. Clyde, and J. K. Davis. 1985. Mycoplasmal respiratory infections. pp. 65-106, In The Mycoplasmas Vol. IV, S. Razin and M. F. Barile (Ed), Academic Press, New York
30 Chang M. W., K. H. Kim, I. D. Park, and M. H. Joh. 1995. Detection of Mycoplasma pneumoniae in clinical specimens of patients by polymerase chain reaction and culture method. J. Korean Soc. Microbiol. 30, 517-525
31 Chang M. W., I. D. Park, K. H. Kim, G. Y. Song, and S. W. Kim. 2005. Tetracycline and erythromycin resistant mutans of the Mycoplasma pneumoniae isolated from patients with resipratory diseases. J. Life Sci. 15, 863-870   과학기술학회마을   DOI   ScienceOn
32 Hempstead P. G. 1990. An improved method for the rapid isolation of chromosomal DNA from Mycoplasma spp. Can. J. Microbiol. 36, 59-64   DOI   ScienceOn
33 Ford O. K., and J. R. Smith. 1974. Nonspecific urethritis associated with a tetracycline- resistant T-mycoplasama. Br. J. Vener Dis. 50, 373-377
34 Foy H., G. E. Kenny, M. K. Cooney, and I. D. Allen. 1979. Long-term epidemiology of infections with Mycoplasma pneumoniae. J. Infect. Dis. 139, 681-687   DOI   ScienceOn
35 Furneri, P. M., G. Rappazzo, M. P. Musumarra, P. Dipietro, L. S. Catania, and L. S. Roccasalva. 2001. Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of M. hominis. Antimicrob. Agents Chemother. 45, 2958-2960   DOI   ScienceOn
36 Arai, S., Y. Gohara, K. Kuwano, and T. Kawashima. 1992. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrobial Agents Chemother. 36, 1322-1324   DOI   ScienceOn
37 Yamaguchi, T., Y. Hirakata, K. Izumikawa, Y. Miyazaki, S. Maesaki, K. Tomono, Y. Yamada, S. Kamihira, and S. Kohno. 2000. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of M. pneumoniae in Japan. Antimicrob. Agents chemother. 44, 1381-1382   DOI
38 Chang M. W., K. H. Kim, I. D. Park, K. H. Kang, E. H. Kong, M. H. Joh, G. Y. Song, and S. W. Kim. 2003. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J. Bacteriol. Virol. 33, 183-191
39 Critchley I. A., M. E. Jones, P. D. Heinze, D. Hubbard, H. D. Engler, A. T. Evangelista, C. Thornsberry, J. A. Karlowsky, and D. F. Sajm. 2002. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumonphila, Mycoplasma pneumoniae and Chlamydia pneumoniae from north America and Europe. Clin. Microbiol. Infect. 8, 214-221   DOI   ScienceOn
40 Smith R. P., A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp. 2004. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. Antimicrb. Agents Chemother. 48, 2081-2084   DOI   ScienceOn
41 Kapusnik-Uner J. E., M. A. Sande, H. F. Chambers. 1996. Antimicrobial agents, tetracycline, chloramphenicol, erythromycin, and miscellaneous antimicrobial agents, pp1123-1153, In Goodman & Gilman,s The pharmacological basis of therapeutics, 9th(ed), McGraw-Hill, New York